Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Verrica Pharmaceuticals Inc. (VRCA)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
2.0000+0.0450 (+2.30%)
At close: 04:00PM EDT
2.0200 +0.02 (+1.00%)
After hours: 07:55PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close5.9200
Open6.0500
Bid1.9600 x 1800
Ask2.0200 x 2900
Day's Range5.8200 - 6.1200
52 Week Range1.8000 - 14.7890
Volume907,875
Avg. Volume285,396
Market Cap55.038M
Beta (5Y Monthly)1.97
PE Ratio (TTM)N/A
EPS (TTM)-1.4570
Earnings DateMar 02, 2022 - Mar 07, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est19.00
  • Zacks

    Verrica (VRCA) Down 64% as Molluscum Drug Gets CRL From FDA

    Verrica Pharmaceuticals' (VRCA) new drug application for VP-102 to treat molluscum contagiosum faces rejection from the FDA for a second time.

  • Benzinga

    RBC Capital Slashes Verrica's Price Target After Third Rejection - What's Next?

    Verrica Pharmaceuticals Inc (NASDAQ: VRCA) was slapped with a third FDA rejection for YCANTH (VP-102) as general contract manufacturing organization challenges continue to plague the approval. RBC Capital Markets has downgraded the stock to Sector Perform from Outperform and lowered the price target from $16 to $4. The analysts note that the issues fall outside of the VP-102's purview. But as per a follow-up call with management, these recurrent offenses highlight the challenges at play with a m

  • MarketWatch

    Verrica's stock slides after getting second complete response letter from FDA

    Shares of Verrica Pharmaceuticals Inc. tumbled 54.5% in premarket trading on Wednesday, the day after the company told investors it received a complete response letter from the Food and Drug Administration relating to the application for the company's experimental treatment for molluscum contagiosum, an infection caused by a poxvirus. The letter cited problems with the contract manufacturing organization Sterling Pharmaceuticals Services LLC, which made the bulk solution drug product used in the

Advertisement
Advertisement